House: health care law's definition of full-time work now 40 hours, not 30

A House bill passed Thursday would change the health care law's definition of full-time work from 30 hours a week to 40 hours a week.

J. Scott Applewhite, Associated Press

Enlarge photo

WASHINGTON House Republicans renewed their election-year assault on President Barack Obama's health care law Thursday, their opposition undimmed just days after Obama celebrated news that more than 7 million Americans had signed up for coverage under the law.

The GOP-led chamber voted 248-179 to change the law's definition of full-time work from 30 hours a week to 40 hours a week. The result would be that fewer workers would get employer-sponsored health coverage and hundreds of thousands more people would be uninsured, according to the Congressional Budget Office.

Republicans, backed by the Chamber of Commerce and other business groups, said the change would restore the traditional definition of full-time work while providing needed relief to businesses that are struggling with increased costs from the health care law. Businesses say they are being forced to cut worker hours, limit full-time jobs and drop health coverage because of the law, which requires businesses with 50 or more full-time workers to provide health coverage or pay penalties.

It was the House GOP's 52nd vote to change, repeal or otherwise uproot Obama's health law, and the measure faced certain death in the Democratic-controlled Senate. Eighteen Democrats joined with all Republicans in approving the bill, named the Save American Workers Act of 2013.

In rancorous debate on the House floor, Democrats accused Republicans of being obsessed with attacking the health law, while Republicans ridiculed Democrats for trying to change what they called a commonly understood definition of full-time work.

"We all know 30 hours isn't full time but that's what Obamacare says," said Rep. Tim Griffin, R-Ark. "Even in France a full-time job is 35 hours a week."

Democrats said the law's 30-hour definition for a full-time workweek was meant to make it harder for employers to avoid covering full-time workers by slightly reducing their hours. Changing the definition to 40 hours would make the requirement virtually meaningless because employers could simply skirt it by knocking full-time workers down to 39-and-a-half hours a week, they said.

Originally posted here:

House: health care law's definition of full-time work now 40 hours, not 30

Huma Rana, M.D., receives 2014 Richard King Award for best publication, Genetics in Medicine

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Kathy Ridgely Beal, M.B.A. kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Huma Q. Rana, MD of Harvard Medical School's Dana Farber Cancer Institute is the recipient of the 2014 Richard King Trainee Award. This award was instituted five years ago by the ACMG Foundation for Genetic and Genomic Medicine to encourage ABMG or genetic counseling trainees in their careers and to foster the publication of the highest quality research in ACMG's peer-reviewed journal, Genetics in Medicine (GIM). Each year the editorial board reviews all articles published in GIM by an ABMG or genetic counseling trainee who was either a first or corresponding author during that year. The manuscript felt to have the most merit is selected by the editorial board and a cash prize awarded at the 2014 ACMG Annual Clinical Genetics Meeting.

Dr. Rana was given the award for her manuscript titled, " Age-Specific Parkinson Disease Risk in GBA Mutation Carriers: Information for Genetic Counseling" which was published in the February 2013 issue of Genetics in Medicine. The corresponding author was Roy Alcalay, MD, MS of Columbia University.

The award is given by the ACMG Foundation and is named for Dr. Richard King in recognition of his instrumental role in creating Genetics in Medicine and serving as the first and founding Editor-in-Chief of the journal.

Eligible trainees include those in the following programs: Clinical Biochemical Genetics; Clinical Cytogenetics; Clinical Molecular Genetics Combined Internal Medicine/Genetics; Combined Pediatrics/Genetics; PhD Medical Genetics and Genetic Counseling.

###

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics and genetic counseling in healthcare. Established in 1992, the ACMG Foundation supports the American College of Medical Genetics and Genomics' mission to "translate genes into health" by raising funds to promote the profession of medical genetics and genomics to medical students, to fund the training of future medical geneticists, to support best-practices and tools for practicing physicians and laboratory directors, to promote awareness and understanding of our work in the general public, and much more.

Read more here:

Huma Rana, M.D., receives 2014 Richard King Award for best publication, Genetics in Medicine

Recurrent head and neck tumors have gene mutations that could be vulnerable to cancer drug

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Allison Hydzik hydzikam@upmc.edu 412-559-2431 University of Pittsburgh Schools of the Health Sciences

SAN DIEGO, April 4, 2014 An examination of the genetic landscape of head and neck cancers indicates that while metastatic and primary tumor cells share similar mutations, recurrent disease is associated with gene alterations that could be exquisitely sensitive to an existing cancer drug. Researchers from the University of Pittsburgh Cancer Institute (UPCI) and Yale University School of Medicine will share their findings during a mini-symposium Sunday at the American Association for Cancer Research Annual Meeting 2014.

About 50 percent of patients diagnosed with head and neck squamous cell cancers already have disease that has spread, or metastasized, to the lymph nodes, explained Jennifer Grandis, M.D., distinguished professor and vice chair of research, Department of Otolaryngology, Pitt School of Medicine, and director of the Head and Neck Program at UPCI, partner with UPMC CancerCenter. About 20 to 30 percent of patients thought to be cured of the disease go on to develop recurrent cancer, which typically doesn't respond to standard treatments.

"We decided to compare the genetic signatures of tumor cells from primary tumors with those from disease that had spread and cancers that were thought cured but then came back in the hopes of getting some clues about how best to guide therapy in these different settings," Dr. Grandis said. "We found that recurrent cancers might have an Achilles' heel we can exploit to kill them."

The team conducted the first whole-exome genetic sequencing study on what Dr. Grandis called its "treasure trove" of frozen patient samples and found similar mutations both in primary tumors and in the lymph nodes to which their cancers had already spread. But there were different mutations in tumors that had recurred after a period of remission that were not found in their original cancers.

"The recurrent tumors carried mutations in a gene area that encodes for DDR2 cell receptors," Dr. Grandis said. "Other studies have shown that DDR2 mutations can confer sensitivity to the cancer drug dasatinib, which could mean that drug has promise in the treatment of recurrent head and neck cancers."

The researchers suggest that further investigation of dasatinib treatment is warranted.

###

See the article here:

Recurrent head and neck tumors have gene mutations that could be vulnerable to cancer drug

2014-2015 Genzyme/ACMG Foundation Medical Genetics Training Award announced

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Kathy Ridgely Beal, MBA kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Paldeep S. Atwal, MD of Stanford University/Lucile Packard Children's Hospital and Jamie J. Barea, MD, of University of California, San Diego were honored as the 2014-2015 recipients of the Genzyme/ACMG Foundation Medical Genetics Training Award in Clinical Biochemical Genetics at the ACMG 2014 Annual Clinical Genetics Meeting in Nashville, TN.

The objective of the two Genzyme/ACMG Foundation Awards is to support a national training program to encourage the recruitment and training of clinicians in the field of clinical biochemical genetics and especially in the diagnosis, management and treatment of individuals with metabolic diseases. Two awardees are given the opportunity to participate in an in-depth clinical and research experience at a premier medical center with expertise and significant clinical volume in the area of biochemical genetics.

The Award grants $75,000 per year to each of two recipients' institution selected by the ACMG Foundation through a competitive process and will provide for the sponsorship of one year of the trainees' clinical genetics subspecialty in biochemical genetics following residency.

Dr. Atwal received his MD from the University Of Glasgow, Scotland; completed his internal medicine residency with The Royal College of Physicians of the United Kingdom at Glasgow Royal Infirmary, and is currently in the second year of residency in Medical Genetics at Stanford University/Lucile Packard Children's Hospital. His research during the award period will focus on perfecting a novel screening and diagnostic platform for diagnosing lysosomal storage diseases by newborn screening and as a clinical screening tool. He will continue his training as part of the Medical Biochemical Genetics Fellowship Program at Baylor College of Medicine.

"I am humbled to be granted the Genzyme/ACMG Foundation award. I am confident the Medical Biochemical Genetics Fellowship will provide a platform for me to provide the best clinical care possible for patients with inborn errors of metabolism including mitochondrial disorders whilst concurrently conducting translational research."

The second award recipient, Dr. Barea, is currently in his second year of residency in Medical Genetics at University of California- San Diego. He said, "I am honored and excited to be one of the recipients of the Genzyme/ACMG Foundation Award. This award will give me a great opportunity as a Biochemical Genetics fellow at UCSD to gain more knowledge and experience through clinical work and research. This experience will allow me to provide the best possible care for all of my future patients." Dr. Barea completed his MD at Tufts University School of Medicine in Boston, MA and a Pediatrics Residency at University of California, San Diego. His research during the Award period will involve a metabolomic study searching for biomarkers in Gaucher disease and Pompe disease.

"The Genzyme/ACMG Foundation Clinical Genetics Award in Clinical Biochemical Genetics is critical to the development of the genetics workforce. Biochemical genetics is undergoing particularly rapid change, as new insights into disease mechanisms are leading to new methods of treatment," said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation.

The rest is here:

2014-2015 Genzyme/ACMG Foundation Medical Genetics Training Award announced

Cleft palate discovery in dogs to aid in understanding human birth defect

April 4, 2014

This puppy is a Nova Scotia Duck Tolling Retriever, the breed with the newly discovered genetic mutation for cleft palate. (Danika Bannasch/UC Davis)

UC Davis School of Veterinary Medicine researchers have identified the genetic mutation responsible for a form of cleft palate in the dog breed Nova Scotia Duck Tolling Retrievers.

They hope that the discovery, which provides the first dog model for the craniofacial defect, will lead to a better understanding of cleft palate in humans. Although cleft palate is one of the most common birth defects in children, affecting approximately one in 1,500 live human births in the United States, it is not completely understood.

The findings appear this week online in the journal PLOS Genetics and are available online at https://tinyurl.com/knr8wb3.

This discovery provides novel insight into the genetic cause of a form of cleft palate through the use of a less conventional animal model, said Professor Danika Bannasch, a veterinary geneticist who led the study. It also demonstrates that dogs have multiple genetic causes of cleft palate that we anticipate will aid in the identification of additional candidate genes relevant to human cleft palate.

Bannasch, who holds the Maxine Adler endowed chair in genetics, explains that common breeding practices have made the dog a unique animal model to help understand the genetic basis of naturally occurring birth defects.

By conducting a genome-wide study of these particular retrievers with a naturally occurring cleft palate, researchers identified a mutation responsible for the development of cleft palate in the breed. Dogs with this mutation also have a shortened lower jaw, similar to humans who have Pierre Robin Sequence. The disorder, a subset of cleft palate, affects one in 8,500 live human births and is characterized by a cleft palate, shortened lower jaw and displacement of the tongue base.

Cleft palate condition occurs when there is a failure in the formation of the secondary palate, which makes up all of the soft palate and the majority of the hard palate. A disruption in the sequential steps of palate development causes a cleft palate and leads to the spectrum of cases that are observed. Children born with cleft palate may develop hearing loss and difficulties with speech and eating. They also may be at increased risk for neurological deficits.

Additional UC Davis researchers include: Zena T. Wolf, a graduate student in the Department of Population Health and Reproduction at the School of Veterinary Medicine, whose thesis topic is the study of craniofacial clefts in dogs; and Assistant Professor Boaz Arzi from the Department of Surgical and Radiological Sciences, School of Veterinary Medicine.

See the rest here:

Cleft palate discovery in dogs to aid in understanding human birth defect

Genetic testing beneficial in melanoma treatment

PUBLIC RELEASE DATE:

4-Apr-2014

Contact: Allison Hydzik hydzikam@upmc.edu 412-559-2431 University of Pittsburgh Schools of the Health Sciences

SAN DIEGO, April 4, 2014 Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

The trial, funded by the National Institutes of Health (NIH), will be presented Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014. It showed that the cancer immune therapy drug ipilimumab appears most likely to prevent recurrence in patients whose cancer shows high expression of immune-related genes.

"We've reached a point in the treatment of melanoma and cancer in general where we're making major improvements in the outcomes of patients through personalized medicine," said lead investigator Ahmad Tarhini, M.D., Ph.D., associate professor of medicine and translational science in Pitt's Department of Medicine and Clinical and Translational Science Institute. "Anti-cancer therapy can be associated with significant side effects and economic costs. Therefore, we have a major interest in the development of tests that may allow us to predict which treatment regimen is most likely to help certain patients, while sparing others the unwanted side effects and cost of medications that are unlikely to work."

Before and after ipilimumab treatment, Dr. Tarhini and his colleagues obtained tumor biopsies used to run genetic tests on the tumors of 32 patients with advanced, stage 3 melanoma who were treated by UPMC. All patients were given standard-of-care surgery, which included complete surgical removal of an advanced tumor.

Patients with tumors that had higher levels of expression of a group of immune-related genes, either before or soon after treatment with ipilimumab, had 63 percent lower risk of cancer recurrence after surgery.

"By validating these findings in a large national trial that also will allow us to investigate other significant biomarker data, we'll seek to develop 'biomarker signatures' that doctors can use to customize melanoma treatment plans. The ultimate goals of therapy are to best treat the cancer in an individualized approach, while avoiding the unnecessary exposure of patients to severe side effects," said Dr. Tarhini.

###

See the rest here:

Genetic testing beneficial in melanoma treatment

Trees tweaked for easier papermaking

LONDON: Researchers have genetically engineered trees that will be easier to break down to produce paper and biofuel. They used genetic engineering to modify lignin to make it easier to break down without adversely affecting the tree's strength. The breakthrough will mean using fewer chemicals, less energy and creating fewer environmental pollutants. Lignin makes up a substantial portion of the cell wall of most plants and is a processing impediment for pulp, paper and biofuel.

Currently lignin must be removed, a process that requires significant chemicals and energy and causes undesirable waste.

"One of the largest impediments for the pulp and paper industry as well as the emerging biofuel industry is a polymer found in wood known as lignin," said Shawn Mansfield, a professor of Wood Science at the University of British Columbia. "We're designing trees to be processed with less energy and fewer chemicals and ultimately recovering more wood carbohydrate than is currently possible." The structure of lignin naturally contains ether bonds that are difficult to degrade. Researchers used genetic engineering to introduce ester bonds into the lignin backbone that are easier to break down chemically. The new technique means that lignin may be recovered more effectively and used in other applications, such as adhesives, insolation, carbon fibres and paint additives. In the future, genetically modified trees could be planted like an agricultural crop, not in forests.

Poplar is a potential energy crop for the biofuel industry because the tree grows quickly and on marginal farmland.

Follow this link:

Trees tweaked for easier papermaking

Dress and behavior of mass shooters as factors to predict and prevent future attacks

PUBLIC RELEASE DATE:

3-Apr-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 3, 2014In many recent incidents of premeditated mass shooting the perpetrators have been male and dressed in black, and may share other characteristics that could be used to identify potential shooters before they commit acts of mass violence. Risk factors related to the antihero, dark-knight persona adopted by these individuals are explored in an article in Violence and Gender, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Violence and Gender website at http://www.liebertpub.com/vio.

In the article "Costuming, Misogyny, and Objectification as Risk Factors in Targeted Violence," Brian Van Brunt, EdD and W. Scott Lewis, The NCHERM Group, LLC (Malvern, PA), suggest reasons why persons who commit mass shootings are drawn to dark popular culture imagery, how these cultural factors may contribute to the violence, and what risk factors could be useful to law enforcement and behavioral investigation teams seeking to identify individuals who might be preparing for an attack.

"'Objectification' of victims and 'costuming' are specific offender behaviors that will give threat assessment teams throughout the world greater insights into the motivation of mass shooters and just how ceremonial their preparations are," says Mary Ellen O'Toole, PhD, Editor-in-Chief of Violence and Gender and Senior FBI Profiler/Criminal Investigative Analyst (ret.). "The value of this information in being able to identify these offenders beforehand based on their behavior so that we can prevent future acts of mass murder is very significant."

###

About the Journal

Violence and Gender is the only peer-reviewed journal focusing on the understanding, prediction, and prevention of acts of violence. Through research papers, roundtable discussions, case studies, and other original content, the Journal critically examines biological, genetic, behavioral, psychological, racial, ethnic, and cultural factors as they relate to the gender of perpetrators of violence. Led by Editor-in-Chief Mary Ellen O'Toole, PhD, Forensic Behavioral Consultant and Senior FBI Profiler/Criminal Investigative Analyst (ret.), Violence and Gender explores the difficult issues that are vital to threat assessment and prevention of the epidemic of violence. Violence and Gender is published quarterly online with Open Access options and in print, and is the official journal of The Avielle Foundation.

About the Publisher

Visit link:

Dress and behavior of mass shooters as factors to predict and prevent future attacks

Future of Logistics and Supply Chain Management globally / in Mexico – Futurist keynote speaker – Video


Future of Logistics and Supply Chain Management globally / in Mexico - Futurist keynote speaker
Future of logistics and supply chain management for audience of Mexico corporate executives. Supply chain innovations, future of retail and e-commerce, futur...

By: Patrick Dixon Futurist Keynote Speaker for Industry Conference

Read the original here:

Future of Logistics and Supply Chain Management globally / in Mexico - Futurist keynote speaker - Video

Build the Ecosystem, not just the apps. Excerpt from Futurist Gerd Leonhard talk on media. – Video


Build the Ecosystem, not just the apps. Excerpt from Futurist Gerd Leonhard talk on media.
This is a short snippet from a recent talk on the future of media I gave in Denmark. Using Tesla as an example I describe the need to co-create and nurture c...

By: Gerd Leonhard

Read this article:

Build the Ecosystem, not just the apps. Excerpt from Futurist Gerd Leonhard talk on media. - Video